Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Saved in:
Bibliographic Details
Title: Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.
Authors: Berdel AF; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Ronnacker J; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Wenge DV; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA., Kolloch LJ; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Berning P; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Center for Molecular and Cellular Oncology, Yale School of Medicine, New Haven, CT., Angenendt L; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland., Brix TJ; Medical Data Integration Center, Institute of Medical Informatics, University of Münster, Münster, Germany., Westermann A; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Wethmar K; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Kessler T; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Kerkhoff A; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Mesters RM; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Reicherts C; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Mikesch JH; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Berdel WE; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Lenz G; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Schliemann C; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Stelljes M; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.
Source: Blood neoplasia [Blood Neoplasia] 2025 Nov 06; Vol. 3 (1), pp. 100181. Date of Electronic Publication: 2025 Nov 06 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2950-3280
DOI:10.1016/j.bneo.2025.100181